Nature Reviews Clinical Oncology

Papers
(The H4-Index of Nature Reviews Clinical Oncology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Tasadenoturev active in DIPG1124
A new standard of care for advanced-stage urothelial carcinoma770
From little subclones grow mighty oaks767
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma742
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC664
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes648
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC623
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care612
Novel ICI–TKI combination improves HCC outcomes599
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety559
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials552
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime547
The emerging roles of circRNAs in cancer and oncology543
The immune landscape of common CNS malignancies: implications for immunotherapy509
Hodgkin lymphoma: great progress with room for improvement506
Gut microbiota in colorectal cancer development and therapy464
Current understanding and management of CAR T cell-associated toxicities461
From ESMO 2022454
From the ESMO Congress 2021396
Mortality is similar with active monitoring365
Contrasting results with second-line CAR T cells in large B cell lymphoma359
Ponatinib superior to imatinib in Ph+ ALL357
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC356
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence350
Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?326
Sacituzumab tirumotecan improves OS in mTNBC325
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials313
Minimal residual disease as a target for liquid biopsy in patients with solid tumours310
Harnessing cytokines and chemokines for cancer therapy306
Predicting cancer outcomes with radiomics and artificial intelligence in radiology300
Humanized mouse models for immuno-oncology research286
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours271
Craniospinal irradiation improves leptomeningeal metastasis control269
Survival benefit with second-line combination in endometrial cancer251
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease249
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer232
Biomarkers for immunotherapy of hepatocellular carcinoma224
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs217
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response213
Improving outcomes in patients with oesophageal cancer211
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070209
Harnessing big data to characterize immune-related adverse events207
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship206
Spatial landscapes of cancers: insights and opportunities203
Approvals in 2022: overall survival, dose optimization, new approvals and beyond202
DREAMseq of therapy for BRAF-mutant melanoma198
New CAPSTONE of SCLC therapy?196
SHINE a light: frontline ibrutinib for MCL195
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions194
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC188
Women with clinically node negative breast cancer can safely avoid axillary surgery185
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC175
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond166
Aumolertinib is effective in NSCLC163
From ESMO 2023: advances in lung cancer162
Circulating tumour DNA — looking beyond the blood160
Prospective comparisons support the use of navigational bronchoscopy153
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer151
Targeting chromosomal instability in patients with cancer149
Mitigating acute chemotherapy-associated adverse events in patients with cancer145
Long-term outcomes following CAR T cell therapy: what we know so far143
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC140
Benefit with ramucirumab in mesothelioma137
Response to neoadjuvant endocrine therapy complements recurrence score136
Multiomics STEP up in correlative analysis of response to CAR T cells130
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress122
From the ESMO Congress 2023121
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM120
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas118
HAIC-FO improves outcomes in HCC117
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma117
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL117
Newly approved cancer drugs in China — innovation and clinical benefit108
Enhancing immunotherapy with tumour-responsive nanomaterials107
Lung cancer in patients who have never smoked — an emerging disease103
Claudin 18.2 as a novel therapeutic target101
Clinical implications of T cell exhaustion for cancer immunotherapy100
From the 2021 ASCO Annual Meeting91
Combining CAR T cells effective in RRMM90
Targeted biopsy reduces detection of clinically insignificant cancer90
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer87
Translating biological insights into improved management of endometrial cancer85
Less-frequent surveillance is noninferior to annual mammography84
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy83
0.10902714729309